|
1
|
Kwakman R, Schrama AM, van Olmen JP, Otten
RH, de Lange-de Klerk ES, de Cuba EM, Kazemier G and Te Velde EA:
Clinicopathological parameters in patient selection for
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
for colorectal cancer metastases: A meta-analysis. Ann Surg.
263:1102–1111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Krebs B, Horvat M, Golle A, Krznaric Z,
Papeš D, Augustin G, Arslani N and Potrč S: A randomized clinical
trial of synbiotic treatment before colorectal cancer surgery. Am
Surg. 79:E340–E342. 2013.PubMed/NCBI
|
|
3
|
Scorsetti M, Comito T, Tozzi A, Navarria
P, Fogliata A, Clerici E, Mancosu P, Reggiori G, Rimassa L,
Torzilli G, et al: Final results of a phase II trial for
stereotactic body radiation therapy for patients with inoperable
liver metastases from colorectal cancer. J Cancer Res Clin Oncol.
141:543–553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng G, Wang H, Zhang X, Yang Y, Wang L,
Du L, Li W, Li J, Qu A, Liu Y and Wang C: Identification and
validation of reference genes for qPCR detection of serum microRNAs
in colorectal adenocarcinoma patients. PLoS One. 8:e830252013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aranda E, Aparicio J, Alonso V,
Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera
R, Vieitez JM and Garcia-Carbonero R: SEOM clinical guidelines for
diagnosis and treatment of metastatic colorectal cancer 2015. Clin
Transl Oncol. 17:972–981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li
T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of
autophagy by the methyltransferase EZH2 through an MTOR-dependent
pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang W, Wang F, Zong G, Liu R, Zhang Y,
Luan Y, Xu L and Xuan J: Prognostic significance of EZH2 expression
in patients with digestive cancers: A meta-analysis. Int J Clin Exp
Med. 8:16043–16049. 2015.PubMed/NCBI
|
|
8
|
Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC,
Cui BB and Yang YM: Expression and clinicopathological significance
of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin
Oncol. 141:661–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scholer-Dahirel A and McLaughlin ME:
Determinants of Wnt/β-catenin pathway dependency in colorectal
cancer. Cell Cycle. 11:9–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Q, Shen S, Liao M, Lian P and Wang X:
NGX6 inhibits cell invasion and adhesion through suppression of
Wnt/beta-catenin signal pathway in colon cancer. Acta Biochim
Biophys Sin (Shanghai). 42:450–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao C, Chen G, Kuan SF, Zhang DH,
Schlaepfer DD and Hu J: FAK/PYK2 promotes the Wnt/β-catenin pathway
and intestinal tumorigenesis by phosphorylating GSK3β. Elife.
4:2015. View Article : Google Scholar
|
|
12
|
Yu Q, Shang LU, Yu H, Yang Z and Xu D:
Silencing of FRAT1 by siRNA inhibits the proliferation of SGC7901
human gastric adenocarcinoma cells. Biomed Rep. 4:223–226. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng L, Li D, Xiang X, Tong L, Qi M, Pu
J, Huang K and Tong Q: Methyl jasmonate abolishes the migration,
invasion and angiogenesis of gastric cancer cells through
down-regulation of matrix metalloproteinase 14. BMC Cancer.
13:742013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Milrot E, Jackman A, Kniazhanski T, Gonen
P, Flescher E and Sherman L: Methyl jasmonate reduces the survival
of cervical cancer cells and downregulates HPV E6 and E7, and
survivin. Cancer Lett. 319:31–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cohen S and Flescher E: Methyl jasmonate:
A plant stress hormone as an anti-cancer drug. Phytochemistry.
70:1600–1609. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cesari IM, Carvalho E, Figueiredo
Rodrigues M, Mendonça Bdos S, Amôedo ND and Rumjanek FD: Methyl
jasmonate: Putative mechanisms of action on cancer cells cycle,
metabolism, and apoptosis. Int J Cell Biol. 2014:5720972014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sofocleous CT, Garcia AR, Pandit-Taskar N,
Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF,
Carrasquillo JA and Kemeny NE: Phase I trial of selective internal
radiation therapy for chemorefractory colorectal cancer liver
metastases progressing after hepatic arterial pump and systemic
chemotherapy. Clin Colorectal Cancer. 13:27–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allegra CJ, Yothers G, O'Connell MJ, Beart
RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A,
et al: Neoadjuvant 5-FU or capecitabine plus radiation with or
without oxaliplatin in rectal cancer patients: A phase III
randomized clinical trial. J Natl Cancer Inst. 107(pii):
djv2482015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi T, Masaki T, Kogawa K, Matsuoka
H and Sugiyama M: Efficacy of gum chewing on bowel movement after
open colectomy for left-sided colorectal cancer: A randomized
clinical trial. Dis Colon Rectum. 58:1058–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M,
Shi D, Chu H, Tong N, Chen J, et al: Clinical potential role of
circulating microRNAs in early diagnosis of colorectal cancer
patients. Carcinogenesis. 35:2723–2730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao F, Chang VT, Cleeland C, Cleary JF,
Mitchell EP, Wagner LI and Fisch MJ: Determinants of pain severity
changes in ambulatory patients with cancer: An analysis from
Eastern Cooperative Oncology Group trial E2Z02. J Clin Oncol.
32:312–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song-Bing H, Hao Z, Jian Z, Guo-Qiang Z,
Tuo H, Dai-Wei W, Wen G, Lin G, Yi Z, Xiao-Feng X, et al:
Inhibition of EZH2 expression is associated with the proliferation,
apoptosis and migration of SW620 colorectal cancer cells in vitro.
Exp Biol Med (Maywood). 240:546–555. 2015.PubMed/NCBI
|
|
23
|
Wang Y, Xiang W, Wang M, Huang T, Xiao X,
Wang L, Tao D, Dong L, Zeng F and Jiang G: Methyl jasmonate
sensitizes human bladder cancer cells to gambogic acid-induced
apoptosis through down-regulation of EZH2 expression by miR-101. Br
J Pharmacol. 171:618–635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma L, Wang X, Jia T, Wei W, Chua MS and So
S: Tankyrase inhibitors attenuate WNT/β-catenin signaling and
inhibit growth of hepatocellular carcinoma cells. Oncotarget.
6:25390–25401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Serafino A, Moroni N, Zonfrillo M,
Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A,
Rasi G and Pierimarchi P: WNT-pathway components as predictive
markers useful for diagnosis, prevention and therapy in
inflammatory bowel disease and sporadic colorectal cancer.
Oncotarget. 5:978–992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan BL, Norhaizan ME, Huynh K, Heshu SR,
Yeap SK, Hazilawati H and Roselina K: Water extract of brewers'
rice induces apoptosis in human colorectal cancer cells via
activation of caspase-3 and caspase-8 and downregulates the
Wnt/β-catenin downstream signaling pathway in brewers' rice-treated
rats with azoxymethane-induced colon carcinogenesis. BMC Complement
Altern Med. 15:2052015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raviv Z, Zilberberg A, Cohen S,
Reischer-Pelech D, Horrix C, Berger MR, Rosin-Arbesfeld R and
Flescher E: Methyl jasmonate down-regulates survivin expression and
sensitizes colon carcinoma cells towards TRAIL-induced
cytotoxicity. Br J Pharmacol. 164:1433–1444. 2011. View Article : Google Scholar : PubMed/NCBI
|
